TWI406663B - 含有氟甲松龍之懸浮型點眼劑 - Google Patents
含有氟甲松龍之懸浮型點眼劑 Download PDFInfo
- Publication number
- TWI406663B TWI406663B TW097111157A TW97111157A TWI406663B TW I406663 B TWI406663 B TW I406663B TW 097111157 A TW097111157 A TW 097111157A TW 97111157 A TW97111157 A TW 97111157A TW I406663 B TWI406663 B TW I406663B
- Authority
- TW
- Taiwan
- Prior art keywords
- container
- castor oil
- eye drop
- polyoxyethylene
- flumethazone
- Prior art date
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 54
- 239000000725 suspension Substances 0.000 title claims description 31
- -1 polyoxyethylene Polymers 0.000 claims abstract description 56
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 53
- 239000004359 castor oil Substances 0.000 claims abstract description 53
- 235000019438 castor oil Nutrition 0.000 claims abstract description 52
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 52
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims abstract description 7
- 229960001048 fluorometholone Drugs 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 229920000609 methyl cellulose Polymers 0.000 claims description 14
- 239000001923 methylcellulose Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 125000006353 oxyethylene group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 description 21
- 239000004372 Polyvinyl alcohol Substances 0.000 description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 description 13
- 229940012356 eye drops Drugs 0.000 description 12
- 235000010981 methylcellulose Nutrition 0.000 description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960003469 flumetasone Drugs 0.000 description 3
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920013716 polyethylene resin Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229920003174 cellulose-based polymer Polymers 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 description 1
- CJXGPJZUDUOZDX-UHFFFAOYSA-N fluoromethanone Chemical compound F[C]=O CJXGPJZUDUOZDX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229960005071 pirenoxine Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Description
本發明係關於一種點眼劑,其為含有氟甲松龍(fluorometholone)之懸浮型點眼劑,該點眼劑中含有0.0001~0.01% (W/V)之聚氧乙烯硬化篦麻油或含有0.0001~0.01% (W/V)之聚氧乙烯篦麻油,以及關於抑制懸浮型點眼劑中含有的氟甲松龍黏著於容器之方法。
氟甲松龍為作為抗炎症性類固醇而供給於醫療的藥物,特別以點眼劑之形態被廣泛使用。因氟甲松龍為難溶於水之藥物,實際使用以懸浮液劑之形態供應。
懸浮液劑因藥物不溶解,使用時必須震盪點眼容器,使沉澱·凝集的藥物均一地再分散而使用,於氟甲松龍之懸浮型點眼劑中亦有相同情形。因此,為了提升氟甲松龍之再分散性已進行各種手段。例如,專利文獻1記載藉由配合非離子性界面活性劑與纖維素系高分子,於再分散性優異且幾乎無凝集塊形成之氟甲松龍懸浮型點眼劑。又,專利文獻2記載含有由液劑之表面張力開始降低的濃度到表面張力之降低停止的濃度範圍內之水溶性纖維素衍生物,而改善氟甲松龍分散粒子之再分散性的水性懸浮液劑。
另一方面,於氟甲松龍之懸浮型點眼劑,因保存狀態(保存姿勢或保存溫度等)之變化,有懸浮型點眼劑中之氟甲松龍黏著於容器內面之情形。作為氟甲松龍黏著容器之一例,認為於靜置保存下沉澱的懸浮型點眼劑中之氟甲松龍,因所
謂容器的橫置之保存姿勢的變化,而曝露於容器的空隙,乾燥後會黏著於容器內面。如此之氟甲松龍對容器之黏著,若容器為直立狀態則不易發生,惟考量流通過程及使用狀況,認為會發生氟甲松龍黏著於容器。又,依容器的保存狀態,不僅於容器的空隙部位,於容器的溶液接觸部位亦有發生氟甲松龍黏著的情形。如此,一旦氟甲松龍黏著於容器,為使氟甲松龍均勻地分散,需長時間的震盪。
因此,期待於流通過程或儲存過程中,懸浮型點眼劑中的氟甲松龍難黏著於容器,亦即抑制黏著於容器之氟甲松龍之懸浮型點眼劑。
專利文獻3中記載著藉由配合羥基丙基甲基纖維素、甲基纖維素等之纖維素系高分子於懸浮液劑中,可使黏著於容器的吡諾克辛(pirenoxine)容易分散於溶液中。又,專利文獻4中記載著含有氯替潑諾(loteprednol etabonate)之水性懸浮液劑中,經由配合選自山梨酸或其鹽及對羥基苯甲酸酯組成之群之至少1種,抑制經沉澱的氯替潑諾粒子對容器之黏著及團塊形成。
然而,專利文獻3及4中未記載抑制氟甲松龍對容器之黏著。
專利文獻1:特開平11-279052號公報
專利文獻2:特開平11-029463號公報
專利文獻3:國際公開2006/030851號小冊
專利文獻4:國際公開2005/053708號小冊
因此,本發明之目的係提供一種點眼劑,係含有氟甲松龍之懸浮型點眼劑,其抑制該點眼劑中之氟甲松龍向容器之黏著。
於是,本發明者等致力研究之結果,發現即使是一般使用的點眼劑之添加劑中,藉由含有聚氧乙烯硬化篦麻油或聚氧乙烯篦麻油,可抑制氟甲松龍黏著於容器。
即,本發明為一種點眼劑,為含有氟甲松龍之懸浮型點眼劑,該點眼劑含有0.0001~0.01% (W/V)之聚氧乙烯硬化篦麻油或0.0001~0.01% (W/V)之聚氧乙烯篦麻油。
又,本發明之另一態樣為一種點眼劑,為含有氟甲松龍之懸浮型點眼劑,該點眼劑含有0.0001~0.01% (W/V)之聚氧乙烯硬化篦麻油或0.0001~0.01% (W/V)之聚氧乙烯篦麻油,且,又含有選自甲基纖維素、聚乙烯吡咯烷酮及聚乙烯醇組成之群之至少1種。
又,本發明之另一態樣為於含有氟甲松龍之懸浮型點眼劑中經由配合0.0001~0.01% (W/V)之聚氧乙烯硬化篦麻油或0.0001~0.01% (W/V)之聚氧乙烯篦麻油而抑制該點眼劑中所含氟甲松龍對容器之黏著之方法。
又,本發明之另一態樣為含有氟甲松龍之懸浮型點眼劑,經由配合0.0001~0.01% (W/V)之聚氧乙烯硬化篦麻油或0.0001~0.01% (W/V)之聚氧乙烯篦麻油,且又配合
甲基纖維素、聚乙烯吡咯烷酮及聚乙烯醇組成之群之至少1種,而抑制該點眼劑中所含氟甲松龍對容器之黏著之方法。
使用於本發明的聚氧乙烯硬化蓖麻油之例,可列舉如聚氧乙烯硬化篦麻油5、聚氧乙烯硬化篦麻油10、聚氧乙烯硬化篦麻油20、聚氧乙烯硬化篦麻油40、聚氧乙烯硬化篦麻油50、聚氧乙烯硬化篦麻油60、聚氧乙烯硬化篦麻油100等。聚氧乙烯硬化篦麻油之濃度係具有抑制點眼劑中的氟甲松龍黏著於容器的效果即可,無特別的限制,較佳為0.0001~0.01%(W/V),更佳為0.001~0.01%(W/V),再更佳為0.001~0.0075%(W/V),最佳為0.001~0.005%(W/V)。
使用於本發明的聚氧乙烯篦麻油之例,可列舉如聚氧乙烯篦麻油5、聚氧乙烯篦麻油9、聚氧乙烯篦麻油15、聚氧乙烯篦麻油35、聚氧乙烯篦麻油40、聚氧乙烯篦麻油60等。聚氧乙烯篦麻油之濃度係具有抑制點眼劑中的氟甲松龍黏著於容器的效果即可,無特別的限制,較佳為0.0001~0.01%(W/V),更佳為0.001~0.01%(W/V),再更佳為0.001~0.0075%(W/V),最佳為0.0001~0.005%(W/V)。
使用於本發明的氟甲松龍之含有量只要可發揮治療效果即可無特別限制,較佳為0.005~0.5%(W/V),更佳為0.02~0.1%(W/V)。現在用於治療之濃度為100ml中0.02g或0.1g。
用於本發明之甲基纖維素之濃度,認為只要有抑制點眼劑中之氟甲松龍黏著於容器之效果的濃度即可無特別限制,較佳為0.00001~0.1%(W/V),更佳為0.00005~0.05
% (W/V),再更佳為0.0001~0.01% (W/V),最佳為0.0001~0.001% (W/V)。
用於本發明之聚乙烯醇之濃度,認為只要有抑制點眼劑中之氟甲松龍黏著於容器之效果的濃度即可無特別限制,較佳為0.00001~0.1% (W/V),更佳為0.00005~0.05% (W/V),再更佳為0.0001~0.01% (W/V),最佳為0.0001~0.001% (W/V)。又,聚乙烯醇可為完全鹼化物或部分鹼化物。
作為用於本發明之聚乙烯吡咯烷酮之例可列舉如聚乙烯吡咯烷酮K25、聚乙烯吡咯烷酮K30、聚乙烯吡咯烷酮K90等。聚乙烯吡咯烷酮之濃度,認為只要有抑制點眼劑中之氟甲松龍黏著於容器之效果的濃度即可無特別限制,較佳為0.00001~0.1% (W/V),更佳為0.00005~0.05% (W/V),再更佳為0.0001~0.01% (W/V),最佳為0.0001~0.001% (W/V)。
保存本發明的點眼劑的容器之材質,係一般點眼劑容器使用之材質即可,例如聚丙烯、丙烯-乙烯共聚物、聚乙烯聚對苯二甲酸乙二醇酯、聚氯乙烯、丙烯酸樹脂、聚苯乙烯等。
本發明之點眼劑可依據市售之氟甲松龍懸浮型點眼劑之製造方法調製,視需要可添加等張劑、防腐劑、pH調節劑、緩衝劑、安定劑等。作為本發明點眼劑之製造方法的代表例,例如下述之方法。首先,於滅菌純水中視需要添加慣用於點眼劑的添加劑之等張劑、防腐劑、pH調節劑、緩衝劑、
安定劑等並溶解之。添加氟甲松龍至該溶液後,使用各種均質機、混合機、磨碾機或超音波等,使其懸浮化。視需要添加pH調節劑來調節pH。又,本發明點眼劑之pH只要為點眼劑通常使用的範圍即可無特別限制,但以4~8之範圍為較佳。
作為等張劑,可列舉例如甘油、丙二醇、聚乙二醇、三棉實糖、蔗糖、山梨糖醇、甘露糖醇、氯化鈉、氯化鉀、氯化鈣、氯化鎂等。
作為防腐劑,可列舉例如氯化苄烷銨、對羥基苯甲酸甲酯、對羥基苯甲酸乙酯、對羥基苯甲酸丙酯、對羥基苯甲酸丁酯、氯丁醇等。
作為pH調節劑,可列舉例如鹽酸、檸檬酸、磷酸、醋酸、氫氧化鈉、氫氧化鉀、碳酸鈉、碳酸氫鈉等。
作為緩衝劑,可列舉例如磷酸、磷酸鹽、硼酸、硼砂、檸檬酸、醋酸、ε-胺基己酸、氨丁三醇(trometamol)等。
作為安定化劑,可列舉例如伊地酸(edetic acid)、伊地酸鈉等。
於後述的實施例各項中詳細地說明,實施例之試驗中顯示,於含有氟甲松龍之懸浮型點眼劑,藉由含有聚氧乙烯硬化篦麻油,可‘抑制氟甲松龍對容器之黏著。即,本發明提供一種點眼劑,為含有氟甲松龍之懸浮型點眼劑,該點眼劑含有聚氧乙烯硬化篦麻油或聚氧乙烯篦麻油。又,本發明提供一種點眼劑,含有聚氧乙烯硬化篦麻油或聚氧乙烯篦麻油,
且,含有選自甲基纖維素、聚乙烯吡咯烷酮及聚乙烯醇組成之群之至少1種。
經由配合各種界面活性劑,調查懸浮型點眼劑中之氟甲松龍對容器之黏著的影響。
作為試驗液劑,調製表1~3所示處方之懸浮型點眼劑。處方中,為使說明簡單,僅顯示比較判定本發明之效果上的必要成分,但配合其他添加物,為氯化苄烷銨、磷酸氫鈉、磷酸二氫鈉、氯化鈉、伊地酸鈉。又,聚氧乙烯硬化篦麻油60係使用日本界面活性劑(Surfacant)工業公司製,甲基纖維素係使用信越化學工業公司製、聚乙烯醇係使用Kuraray公司製,聚乙烯吡咯烷酮係使用BASF公司製者。
又,表中之縮寫如以下所示者。
FML:氟甲松龍
HCO60:聚氧乙烯硬化篦麻油60
MC:甲基纖維素
PVP:聚乙烯吡咯烷酮
PVA:聚乙烯醇
Tw80:聚山梨酸酯80
MYS:聚氧40硬脂酸酯(Polyoxyl 40 Stearate)
表1~3中之試驗液劑之調製依據以下之方法進行。
將含氟甲松龍之濃厚懸浮液(1%)經攪拌機攪拌約1小
時而調製,進而經高速回轉式攪拌機攪拌約30分鐘。此濃厚懸浮液以氟甲松龍之濃度為所定濃度的方式稀釋於基劑(由上述處方去除氟甲松龍者)。
將依據上述而調製的處方1~7及比較處方1~13的試驗液劑填充至5 ml的點眼容器(聚乙烯樹脂製)各10瓶。使該容器直立,於25℃/40% RH的條件下保存1週後,慢慢地使容器倒立,再於相同條件下保存2週。保存結束後,檢查各處方對抑制氟甲松龍黏著於容器底部之效果。
依據效果判定方法(正立;1週→倒立;2週),處方1~7之結果如表4所示。
依據效果判定方法(正立;1週→倒立;2週),比較處方1~7之結果如表5所示。
依據效果判定方法(正立;1週→倒立;2週),比較處方8~13之結果如表6所示。
表4~6中的數字係表示相對於試驗個數10個,使容器旋轉20回後,進而以手震盪容器100回後,氟甲松龍黏著於容器底部之樣品數。所謂氟甲松龍黏著的樣品,係表示氟甲松龍為粒子而可以肉眼觀察的狀態的樣品。
由表4~6清楚可知,含有為界面活性劑之聚氧乙烯硬化篦麻油之處方1~7,相較於含有其他界面活性劑之比較處方1~13,氟甲松龍黏著於容器底部之樣品數皆變少。即,即使一般使用的點眼劑之界面活性劑中,藉由含有聚氧乙烯硬化篦麻油,顯示抑制氟甲松龍對容器之黏著。
又,由表4~6清楚可知,含有甲基纖維素之處方1~3,及含有聚乙烯醇之處方7,相較於含有聚乙烯吡咯烷酮之處方4~6,氟甲松龍黏著於容器底部之樣品數變少。即,含有聚氧乙烯硬化篦麻油之點眼劑中,含有甲基纖維素或聚乙烯醇之一方,顯示更抑制氟甲松龍對容器之黏著效果。
依據聚氧乙烯硬化篦麻油之配合濃度,調查氟甲松龍對容器之黏著。
作為試驗液劑,調製表7~8所示處方之懸浮型點眼劑。處方中,為使說明簡單,僅顯示比較判定本發明之效果上的必要成分,但配合其他添加物之氯化苄烷銨、磷酸氫鈉、磷
酸二氫鈉、氯化鈉、伊地酸鈉。又,表中之縮寫與表1~3相同。又,聚氧乙烯硬化篦麻油60係使用日本界面活性劑工業公司製,甲基纖維素係使用信越化學工業公司製,聚乙烯醇係使用Kuraray公司製,聚乙烯吡咯烷酮係使用BASF公司製者。
表7~8中之試驗液劑之調製依據以下之方法進行。
將含氟甲松龍之濃厚懸浮液(1%)經攪拌機攪拌約1小時而調製,進而經高速回轉式攪拌機攪拌約30分鐘。此濃厚懸浮液以氟甲松龍之濃度為所定濃度的方式稀釋於基劑(由
上述處方去除氟甲松龍者)。又,視氟甲松龍之分散性,適宜添加聚氧乙烯硬化篦麻油60於上述濃厚懸浮液。
將依據上述而調製的處方8~17的試驗液劑填充至5 ml的點眼容器(聚乙烯樹脂製)各10瓶。使該容器直立,於25℃/40% RH的條件下保存1週後,慢慢地使容器倒立,再於相同條件下保存2週。保存結束後,檢查各處方對抑制氟甲松龍黏著於容器底部之效果。
依據效果判定方法(正立;1週→倒立;2週),處方8~12之結果如表9所示。
依據效果判定方法(正立;1週→倒立;2週),處方13~17之結果如表10所示。
表9~10中的數字係表示相對於試驗個數10個,使容器旋轉20回後,進而以手震盪容器100回後,氟甲松龍黏著於容器底部之樣品數。所謂氟甲松龍黏著的樣品,係表示氟甲松龍為粒子而可以肉眼觀察的狀態的樣品。
由表9~10清楚可知,處方8~17,與比較處方1~13相較,氟甲松龍黏著於容器底部之樣品數皆減少,此次試驗的聚氧乙烯硬化篦麻油任一者之濃度中亦認為有氟甲松龍之容器黏著抑制效果。抑制效果以配合濃度為0.0025% (W/V)之處方為最高。
依據實施例1的調製法製得下述之製劑。又,下述製劑例中,各成份的配合量係100 ml中之含量。
上述處方中,將氟甲松龍之配合量變更為0.02 g,聚氧乙烯硬化篦麻油60之配合量變更為0.001、0.005、0.0075或0.01 g。又,甲基纖維素之配合量變更為0.00001、0.00005、0.0005、0.001、0.005或0.01 g,可製得和製劑例1相同之製劑。
上述處方中,氟甲松龍之配合量變更為0.02 g,聚氧乙烯硬化篦麻油60之配合量變更為0.001、0.005、0.0075或0.01 g,又,聚乙烯醇之配合量變更為0.00001、0.00005、0.0005、0.001、0.005或0.01 g,亦可獲得相同於製劑例2之製劑。
本發明提供一種點眼劑,係含有氟甲松龍之懸浮型點眼劑,該點眼劑含有聚氧乙烯硬化篦麻油或聚氧乙烯篦麻油。又,本發明提供一種點眼劑,係含有聚氧乙烯硬化篦麻油或聚氧乙烯篦麻油,且含有選自甲基纖維素、聚乙烯吡咯烷酮及聚乙烯醇組成之群之至少一種者。
Claims (2)
- 一種抑制氟甲松龍黏著於容器之點眼劑,其係含有氟甲松龍(fluorometholone)之懸浮型點眼劑,該點眼劑含有0.0001~0.01%(W/V)之聚氧乙烯硬化篦麻油(polyoxyethylene hydrogenated castor oil)及0.0001~0.01%(W/V)之甲基纖維素。
- 一種抑制點眼劑所含有之氟甲松龍黏著於容器之方法,其係為於含有氟甲松龍之懸浮型點眼劑中,藉由摻合0.0001~0.01%(W/V)之聚氧乙烯硬化篦麻油及0.0001~0.01%(W/V)之甲基纖維素,而抑制該點眼劑中所含有之氟甲松龍黏著於容器之方法。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007087779 | 2007-03-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200846009A TW200846009A (en) | 2008-12-01 |
| TWI406663B true TWI406663B (zh) | 2013-09-01 |
Family
ID=39830881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097111157A TWI406663B (zh) | 2007-03-29 | 2008-03-28 | 含有氟甲松龍之懸浮型點眼劑 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP5087448B2 (zh) |
| KR (1) | KR101475965B1 (zh) |
| CN (1) | CN101646441B (zh) |
| TW (1) | TWI406663B (zh) |
| WO (1) | WO2008123396A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013016897A2 (pt) * | 2010-12-28 | 2019-09-24 | Rohto Pharma | composição oftálmica aquosa |
| CN103565742A (zh) * | 2012-07-25 | 2014-02-12 | 天津金耀集团有限公司 | 氟米龙滴眼液 |
| JP6077860B2 (ja) * | 2013-01-16 | 2017-02-08 | 東レ株式会社 | 液剤 |
| EP3639854B1 (en) | 2017-06-16 | 2026-01-07 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy |
| WO2018230713A1 (ja) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| WO2022210784A1 (ja) * | 2021-03-30 | 2022-10-06 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
| KR102356603B1 (ko) * | 2021-08-05 | 2022-02-08 | 지엘팜텍주식회사 | 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 |
| CN119679711A (zh) * | 2025-01-16 | 2025-03-25 | 苏州乐珠制药有限公司 | 一种氟米龙混悬滴眼液及其制备工艺 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0995435A1 (en) * | 1997-05-14 | 2000-04-26 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations with excellent redispersibility |
| CN1288372A (zh) * | 1998-01-22 | 2001-03-21 | 参天制药株式会社 | 氟米龙眼用混悬液 |
| JP2004315472A (ja) * | 2003-04-18 | 2004-11-11 | Yuuwa Shoji:Kk | 眼科用製剤、点眼液、人工涙液、コンタクトレンズケアー用品、洗眼液、および眼軟膏 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0796495B2 (ja) * | 1988-02-23 | 1995-10-18 | 参天製薬株式会社 | 水性懸濁点眼剤 |
| JP3402195B2 (ja) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
| JP3418751B2 (ja) | 1998-01-22 | 2003-06-23 | 参天製薬株式会社 | フルオロメトロン懸濁型点眼剤 |
| US20040097592A1 (en) * | 2000-09-13 | 2004-05-20 | Kenji Morishima | Eye drops |
-
2008
- 2008-03-28 KR KR1020097020221A patent/KR101475965B1/ko not_active Expired - Fee Related
- 2008-03-28 JP JP2008085324A patent/JP5087448B2/ja not_active Expired - Fee Related
- 2008-03-28 TW TW097111157A patent/TWI406663B/zh active
- 2008-03-28 CN CN2008800105311A patent/CN101646441B/zh not_active Expired - Fee Related
- 2008-03-28 WO PCT/JP2008/056015 patent/WO2008123396A1/ja not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0995435A1 (en) * | 1997-05-14 | 2000-04-26 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations with excellent redispersibility |
| CN1288372A (zh) * | 1998-01-22 | 2001-03-21 | 参天制药株式会社 | 氟米龙眼用混悬液 |
| JP2004315472A (ja) * | 2003-04-18 | 2004-11-11 | Yuuwa Shoji:Kk | 眼科用製剤、点眼液、人工涙液、コンタクトレンズケアー用品、洗眼液、および眼軟膏 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200846009A (en) | 2008-12-01 |
| JP2008266323A (ja) | 2008-11-06 |
| CN101646441A (zh) | 2010-02-10 |
| CN101646441B (zh) | 2012-09-12 |
| KR101475965B1 (ko) | 2014-12-23 |
| JP5087448B2 (ja) | 2012-12-05 |
| KR20100014632A (ko) | 2010-02-10 |
| WO2008123396A1 (ja) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI406663B (zh) | 含有氟甲松龍之懸浮型點眼劑 | |
| JP5250551B2 (ja) | レバミピド含有水性懸濁液剤及びその製造方法 | |
| EP2408302A1 (en) | Ophthalmic formulations of ketotifen and methods of use | |
| JP5729109B2 (ja) | ソフトコンタクトレンズ用眼科組成物 | |
| CN102946855B (zh) | 含有妥布霉素和地塞米松的局部用眼科混悬剂 | |
| JP3418751B2 (ja) | フルオロメトロン懸濁型点眼剤 | |
| JP2010265261A (ja) | レボカバスチン懸濁型点眼剤 | |
| JP2010204597A (ja) | ソフトコンタクトレンズ用組成物及びソフトコンタクトレンズへの吸着抑制方法 | |
| WO1999037286A1 (en) | Fluorometholone suspension eye drops | |
| TW202335664A (zh) | 眼科組成物 | |
| JP5834427B2 (ja) | ソフトコンタクトレンズへの吸着抑制方法 | |
| JP5276591B2 (ja) | ピレノキシン含有二液性点眼剤 | |
| CN102361630A (zh) | 制备低溶解度物质的混悬剂的方法 | |
| JPWO2005053708A1 (ja) | ロテプレドノールエタボネート水性懸濁液剤 | |
| CN108136036A (zh) | 包含瑞巴派特的新型眼科组合物及其制备方法 | |
| JP4958818B2 (ja) | ピレノキシンを含有する懸濁型水性液剤 | |
| JP2006111621A (ja) | ピレノキシン懸濁型点眼剤 | |
| JP2009073828A (ja) | 点眼剤 | |
| US12023344B2 (en) | Topical otic, ophthalmic, and nasal corticosteroid formulations | |
| EP4595960A1 (en) | Combination preparation containing heterocyclidene acetamide derivative | |
| WO2006030851A1 (ja) | ピレノキシン懸濁型点眼剤 | |
| JP2006104114A (ja) | 粘膜適用組成物 | |
| JP2006131580A (ja) | 粘膜適用組成物 | |
| HK40071854B (zh) | 药物组合物 |